ストックスクリーナーアプリを入手
2.16
3.57%
-0.08
アフターアワーズ：
2.16
前日終値:
$2.24
開ける：
$2.13
24時間の取引高:
64,253
Relative Volume:
1.23
時価総額：
$17.81M
収益：
$2.00M
当期純損益:
$-11.43M
株価収益率:
-1.1037
EPS:
-1.957
ネットキャッシュフロー:
$-10.05M
1週間 パフォーマンス:
-1.14%
1か月 パフォーマンス:
+3.35%
6か月 パフォーマンス:
-69.79%
1年 パフォーマンス:
-24.48%
1日の値動き範囲:
$2.12
$2.22
1週間の範囲:
$2.10
$2.25
52週間の値動き範囲:
$1.81
$12.37
Lipocine Inc Stock (LPCN) Company Profile
名前
Lipocine Inc
セクター
電話
801 994 7383
住所
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
2.16 | 18.71M | 2.00M | -11.43M | -10.05M | -1.957 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-06 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-06-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-12-10 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-01-11 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | 再開されました | H.C. Wainwright | Buy |
| 2016-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2015-07-22 | 開始されました | ROTH Capital | Buy |
| 2015-06-23 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Lipocine Inc (LPCN) 最新ニュース
Form 8K Lipocine Inc For: 11 September By Investing.com - Investing.com Australia
Lipocine Inc (NASDAQ: LPCN) Share Price, LPCN Stock News, LPCN Share Price & Updates - Kalkine
Lipocine Cuts ATM Sales Agent Fee to Up to 3.0% - minichart.com.sg
Lipocine updates sales agent fee agreement with A.G.P./Alliance Global Partners - Investing.com India
Lipocine Updates Sales Agreement Fee Structure with A.G.P. - TipRanks
Lipocine (LPCN) sets sales agent commissions at up to 3% - Stock Titan
Form 8K Lipocine Inc For: 10 September By Investing.com - Investing.com South Africa
Lipocine to present at H.C. Wainwright conferen... - Pluang
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Lipocine to Present at H.C. Wainwright Investment Conference - TipRanks
Webcast to highlight Lipocine (LPCN) oral drug pipeline - Stock Titan
Lipocine Stock Price Forecast. Should You Buy LPCN? - StockInvest.us
Lipocine (LPCN) Advances 3.06% to $2.35, Testing Key Resistance ZoneSeasonality Effect - vinanet.vn
Lipocine (LPCN) Jumps 5.35% to $2.27 as Buyers Target $2.38 ResistanceTRIN Signal - vinanet.vn
Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight - Yahoo Finance
Lipocine (LPCN) Q2 2026 Results: The Bottom-Line Figure Beats Its Comparison for the Current Session; After Results: The Share Price Moves Only Slightly under the Current SnapshotGross Profit Margin - vinanet.vn
Lipocine (LPCN) adds Grissinger to pay panel at $7,500 a year - Stock Titan
Lipocine (LPCN) Q2 2026 Scorecard: EPS Comes in Above Forecast in Latest Trading; Price Reaction - vinanet.vn
Lipocine (LPCN) Q2 2026 Filing Snapshot: Reported EPS Tops Expectations in Latest Trading; Immediate Response: The Stock Ends Down 0.49% in the Current UpdateEarnings Preview - dars.gov.et
Lipocine Inc. (LPCN) Edges Higher to $2.12, Holding Above Key SupportAdvance Decline Volume - dars.gov.et
Lipocine (LPCN): Squadron funds report 810,000 shares, a 9.8% ownership stake - Stock Titan
LPCN Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus as Revenue Remains Absent - vinanet.vn
Weekly Recap: Q2 revenue drop and Brilzio partner search - TradingView
LPCN Q2 2026 Earnings: Loss Narrower Than Expected, Shares Ease 1.41%Earnings Turnaround - vinanet.vn
Lipocine Inc. (NASDAQ: LPCN) awards director 2,000 stock options - Stock Titan
Lipocine Inc. (LPCN) director Grissinger files initial ownership statement - Stock Titan
Lipocine Inc (LPCN) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Lipocine files Form 3 initial beneficial ownership statement for director Michael Grissinger - Bitget
Lipocine Inc (LPCN) Stock News Today - TradingKey
Lipocine (LPCN) Stock Analysis: Flat at $2.13, What's Next 2026-08-07Median Line - dars.gov.et
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Lipocine (LPCN) and High Tide (HITI) - The Globe and Mail
Lipocine (LPCN) Slips 1.8% to $2.13 as Biotech Stock Holds Above Key $2.02 SupportMcClellan Oscillator - dars.gov.et
A. G. P. Maintains Lipocine(LPCN.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Lipocine Inc (LPCN) Earnings Date & Reports & Earnings News - TradingKey
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 - Morningstar
Lipocine Q2 net loss widens as revenue declines - TradingView
Lipocine posts $2.6 million Q2 net loss as revenue falls - Quiver Quantitative
Lipocine Inc. Q2 2026: Revenue $190099 EPS $(0.32) — 10-Q Summary - TradingView
Lipocine (NASDAQ: LPCN) widens H1 loss but extends cash runway to 2027 - stocktitan.net
Lipocine Appoints Michael J. Grissinger to Board of Directors - Morningstar
Lipocine Appoints Industry Veteran Grissinger to Board - TipRanks
Lipocine appoints Michael Grissinger to board of directors By Investing.com - Investing.com Australia
Lipocine appoints Michael Grissinger to board of directors - Investing.com India
Lipocine Inc. Announces Appointment of Michael J. Grissinger to Board of Directors, Effective August 3, 2026 - marketscreener.com
Lipocine Inc expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Lipocine Inc (LPCN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lipocine Inc (LPCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LPCN|Lipocine Inc|Price:2.420|Chg%:+0.065 - TradingKey
Lipocine Inc (LPCN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lipocine Inc (LPCN) Income Statement - TradingKey
Lipocine Inc (LPCN) Balance Sheet - TradingKey
Lipocine Inc (LPCN) 財務データ
収益
当期純利益
現金流量
EPS
Lipocine Inc (LPCN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Higuchi John W. | Director |
Apr 06 '26 |
Buy |
2.05 |
123,000 |
252,150 |
163,797 |
| Patel Mahesh V. | Chief Executive Officer |
Apr 06 '26 |
Buy |
2.03 |
25,000 |
50,750 |
160,679 |
| Patel Mahesh V. | Chief Executive Officer |
Apr 02 '26 |
Buy |
2.02 |
25,000 |
50,500 |
135,679 |
0.14%
0.15%
大文字化:
|
ボリューム (24 時間):